{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:30:57Z","timestamp":1790497857442,"version":"4.1.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:p>Human epidermal growth factors play an important role in ovarian carcinogenesis and are evaluated for prognostic and possible therapeutic roles in high-grade serous ovarian malignancies. The present study was undertaken to evaluate the expression of human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) in advanced stage serous carcinoma and their influence on prognosis. The expression of HER2 and EGFR was studied in 59 cases of stage III and IV ovarian serous carcinomas by immunohistochemistry and fluorescent <jats:italic toggle=\"yes\">in situ<\/jats:italic> hybridization. Of the 48 interpretable tumors for HER2, 6 tumors (12.5%) were scored as positive, 14 (29%) as equivocal and 28 tumors (58.5%) were negative by immunohistochemistry, while only 2\/48 (4%) showed frank amplification by fluorescent <jats:italic toggle=\"yes\">in situ<\/jats:italic> hybridization with \u22654 copies per cell. HER2 gene expression measured by quantitative polymerase chain reaction had good positive correlation with both protein expression and gene amplification. Although EGFR expression was seen in 32% of tumors, none of the tumors positive for HER2 protein or gene amplification had co-expression of EGFR indicating mutual exclusivity of their expression. Gene expression of both proteins also confirmed their inverse correlation (Pearsons CC=\u22120.15, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.3). Further there was no influence of protein or gene expression of these markers on the overall survival. In conclusion, HER2 and EGFR are expressed in a small percentage of tumors and the mutual exclusivity of these markers precludes the possibility of dual targeting with anti-HER2 and anti-EGFR therapy in advanced stage high-grade serous ovarian carcinoma.<\/jats:p>","DOI":"10.1097\/pgp.0000000000000678","type":"journal-article","created":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T19:26:38Z","timestamp":1586892398000},"page":"49-55","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Expression of HER2 and EGFR Proteins in Advanced Stage High-grade Serous Ovarian Tumors Show Mutual Exclusivity"],"prefix":"10.1097","volume":"40","author":[{"given":"Julian","family":"Crasta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayatri","family":"Ravikumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savitha","family":"Rajarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumangala","family":"Gali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran A.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Vallikad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Prabhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,4,13]]},"reference":[{"key":"R2-20250802","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1158\/1078-0432.CCR-14-1312","article-title":"New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances","volume":"20","author":"Liu","year":"2014","journal-title":"Clin Cancer Res"},{"key":"R3-20250802","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2644","article-title":"The biology of ovarian cancer: new opportunities for translation","volume":"9","author":"Bast","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"R4-20250802","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ygyno.2014.10.024","article-title":"Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma","volume":"136","author":"Bonneau","year":"2015","journal-title":"Gynecol Oncol"},{"key":"R5-20250802","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.hoc.2011.10.004","article-title":"Current surgical management of ovarian cancer","volume":"26","author":"Schorge","year":"2012","journal-title":"Hematol Oncol Clin North Am"},{"key":"R6-20250802","first-page":"519","article-title":"Ovarian cancer: diagnostic, biological and prognostic aspects","volume":"10","author":"Davidson","year":"2014","journal-title":"Womens Health"},{"key":"R7-20250802","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s12032-014-0391-z","article-title":"Expressions of fatty acid synthase and HER2 are correlated with poor prognosis of ovarian cancer","volume":"32","author":"Cai","year":"2015","journal-title":"Med Oncol"},{"key":"R8-20250802","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0959-8049(97)10157-5","article-title":"ERBB2 oncogene in human breast cancer and its clinical significance","volume":"34","author":"Revillion","year":"1998","journal-title":"Eur J Cancer"},{"key":"R9-20250802","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1200\/JCO.2004.05.142","article-title":"Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma","volume":"22","author":"Stoecklein","year":"2004","journal-title":"J Clin Oncol"},{"key":"R10-20250802","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"R11-20250802","first-page":"166","article-title":"HER2-directed therapy for metastatic breast cancer","volume":"27","author":"Jelovac","year":"2013","journal-title":"Oncology (Williston Park)"},{"key":"R12-20250802","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrclinonc.2015.213","article-title":"Kinase inhibitors and monoclonal antibodies in oncology: clinical implications","volume":"13","author":"Gharwan","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"R13-20250802","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.2003.10.104","article-title":"Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group","volume":"21","author":"Bookman","year":"2003","journal-title":"J Clin Oncol"},{"key":"R14-20250802","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.3892\/ijo.2016.3678","article-title":"Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs","volume":"49","author":"Puvanenthiran","year":"2016","journal-title":"Int J Oncol"},{"key":"R15-20250802","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40291-013-0070-3","article-title":"Comprehensive profiling of EGFR\/HER receptors for personalized treatment of gynecologic cancers","volume":"18","author":"Reyes","year":"2014","journal-title":"Mol Diagn Ther"},{"key":"R16-20250802","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000086958","article-title":"HER2\/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study","volume":"68","author":"Verri","year":"2005","journal-title":"Oncology"},{"key":"R17-20250802","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jmoldx.2013.11.003","article-title":"Separate quality-control measures are necessary for estimation of RNA and methylated DNA from formalin-fixed, paraffin-embedded specimens by quantitative PCR","volume":"16","author":"Korlimarla","year":"2014","journal-title":"J Mol Diagn"},{"key":"R18-20250802","doi-asserted-by":"crossref","first-page":"19662","DOI":"10.18632\/oncotarget.24791","article-title":"Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer","volume":"9","author":"Puvanenthiran","year":"2018","journal-title":"Oncotarget"},{"key":"R19-20250802","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1309\/AJCPV2I0HGPMGBSQ","article-title":"Emerging technologies for assessing HER2 amplification","volume":"132","author":"Penault-Llorca","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"R20-20250802","doi-asserted-by":"crossref","first-page":"589","DOI":"10.18632\/genesandcancer.142","article-title":"EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review","volume":"8","author":"Mehner","year":"2017","journal-title":"Genes Cancer"},{"key":"R21-20250802","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40291-013-0024-9","article-title":"HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies","volume":"17","author":"English","year":"2013","journal-title":"Mol Diagn Ther"},{"key":"R22-20250802","doi-asserted-by":"crossref","first-page":"852748","DOI":"10.1155\/2014\/852748","article-title":"Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Mol Biol Int"},{"key":"R23-20250802","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/jclinpath-2011-200616","article-title":"HER2 expression in ovarian carcinoma: caution and complexity in biomarker analysis","volume":"65","author":"McCaughan","year":"2012","journal-title":"J Clin Pathol"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000678","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:05:16Z","timestamp":1754161516000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,13]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/pgp.0000000000000678","relation":{},"ISSN":["0277-1691"],"issn-type":[{"value":"0277-1691","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,13]]}}}